When motivation disappears: apathy, depression and what helps
Masud Husain describes apathy as a distinct brain state, Huberman explains anhedonia in depression and why behavioral tools are hard to use, and the ketamine episode shows new ways to restore drive. It helps readers tell ordinary low motivation from a condition that needs care.
The Short Version
Losing your drive is not one thing. Oxford neurologist Masud Husain describes apathy as its own brain state: a breakdown in the circuits that weigh reward against effort. It can wipe out motivation without making a person sad, and it can show up without depression at all [1]. Andrew Huberman describes the anhedonia of depression, the flat inability to enjoy anything, as part of a wider biological condition. It involves several neurochemical systems, hormones, stress and genes, and it is cruel in a specific way: the behavioral tools that raise mood need exactly the energy depression takes away [2]. Ketamine points to a newer way to restore drive. It seems to rewire the reward and "disappointment" circuits within days, but only lasting behavior keeps the effect going [3]. Taken together, the three conversations give readers a way to tell an ordinary slump from a condition that needs a professional, and they point to what actually helps in each case.
Table of contents
What They Said
Masud Husain: apathy is a biological calculation that can break
From "personality" to biology. Husain says that about 15 years ago he thought of motivation as a matter of character: "Like many people, I might think, someone's lazy or they're highly motivated, but that's a sort of psychological state. It's a personality." [1] One patient changed his mind. David was a productive, well-liked man in his 30s who suddenly stopped caring about anything. Antidepressants did not help. He lost his job and his apartment and sat in a chair all day at a friend's home, needing prompts even to shower. Yet he wasn't unhappy [1]. When Husain asked why he didn't listen to music, which he enjoyed, David said setting up his stereo would take too much effort. It was about five minutes of work [1].
MRI scans showed two tiny strokes in the basal ganglia, in the ventral striatum, the region known in animals as the nucleus accumbens [1]. Husain describes these deep structures as ancient, going back some 360 million years to the lamprey, and says they link motivation signals to action [1]. The treatment story is the key clinical detail. The team first tried L-dopa, the Parkinson's drug Oliver Sacks describes in Awakenings, and it "seemed to make absolutely no difference, behaviorally to David, or on our tests of reward sensitivity" [1]. They were about to give up. Then Husain tried a dopamine agonist, ropinirole, which acts directly on D2 and D3 receptors instead of serving as a building block for dopamine [1]. Three months later David arrived showered and in a suit, with a new job and a new girlfriend [1]. For Husain, the case showed that motivation has a biology that can be taken apart, and sometimes repaired [1].
Apathy is common in brain disease. David's case was dramatic, but Husain stresses that "apathy is really common across neurological disorders" [1]. Stroke, Alzheimer's disease, Parkinson's disease and inflammatory disorders such as multiple sclerosis can all produce it when they hit this circuitry [1]. In his framing, apathy is the opposite of motivation, and Huberman notes in the introduction that, "perhaps surprisingly, apathy is separate from one's desire for something" [1].
The effort-versus-reward trade-off. Husain describes motivation as a neuroeconomic decision. On a free day you might have 20 options. The brain values each by its expected reward and its cost in physical, cognitive, social or emotional effort, and the winner becomes your motivated behavior [1]. Across neurological disorders his team found a consistent signature: "everyone is willing to work for high rewards. But the difference between motivated people and apathetic people is at the level of the low rewards." [1] That fits David exactly: music still mattered to him, but a small reward no longer justified a small effort.
Husain also notes that apathy can be patchy. It can be behavioral, social, emotional or cognitive, so someone might be socially apathetic but intellectually curious [1]. He calls the basal ganglia pathway a "final common pathway," while the values fed into it are computed elsewhere in the brain. That helps explain why a failure in one area doesn't have to spread to everything [1].
Deciding itself costs more. The most surprising finding comes from healthy Oxford students. In an MRI scanner, they judged whether different rewards were worth different amounts of physical effort. As with patients, the more apathetic students still worked for high rewards but turned down low ones [1]. Yet they showed more activity in the ventral striatum and medial frontal areas while deciding. Husain's reading: "apathetic people use more brain energy when they're making this decision." [1] There is a real cost to thinking about effort on top of the effort itself. Huberman calls it a compounding cost that can take some people "out of the game" [1]. He connects it to "activation energy," recalling a Stanford PhD student, Lauren Case, whose advisor praised her for simply getting up and running the next experiment [1]. Husain adds a personal contrast: from long Oxford tea-room discussions to MIT, where colleagues would say let's do that tonight [1].
Practical levers. If motivation is reward weighed against effort, there are two levers: raise the reward or shrink the effort [1]. Huberman describes a comedy skit in which a man won't hang pictures when asked, but jumps up when asked to teach how. Husain says this works because the reward itself changed [1]. His other tools: plan the day or week in advance, because "Every decision has a cost" and making many decisions at once may lower the overall burden; break big projects into smaller if-then steps, turning a mountain into a series of mounds; get recognition along the way, since a manager's "well done" is a reward before the project ends; and just start, because starting is often a big motivational pull [1]. The two also discuss how perceived effort differs from actual effort. Huberman describes endurance athlete Ken Rideout telling rivals he never gets tired and then pulling away. As Huberman puts it, the hill is still the hill, which suggests part of what we feel as effort was a mental cost all along [1].
Starting, persevering, learning. Husain describes motivation in stages: starting, persevering, and then the pleasant or unpleasant outcome, which feeds reinforcement learning and changes how we value that option next time. Dopamine is involved in that learning too [1]. Starting isn't enough; finishing matters as much [1]. Huberman offers his "chop wood, carry water" idea and argues that "you find your passion by getting good at effort in things that you're not passionate about." [1] Husain agrees that waiting for passion to arrive may not work [1]. On long goals, Husain doubts the basal ganglia alone keep time over years. He thinks such goals are built by higher-level planning in the frontal cortex, and he admits that this kind of planning "has not been studied in great detail" [1]. Huberman adds that paying attention to small wins also means noticing small failures, and that perseverance for him means making the pain a shorter experience than the win so that "you can do hard things" becomes part of your self-concept [1].
Where apathy meets depression. Husain warns that generalizing failures in an unhelpful way ("I'm bad at everything") can shade into depression [1]. His central distinction is that apathy and depression can occur separately or together. David had pure apathy, while some depressed people remain motivated [1].
The self can change. Husain's broader point is that the self is not immutable. [1] Thyroid hormone imbalances, stroke, Alzheimer's and brain injury can all change personal and social identity [1]. He is not an expert on psychedelics but notes emerging research on anhedonia [1]. He also flags a warning sign: healthy older adults who score high on apathy questionnaires have roughly twice the risk of developing Alzheimer's [1]. Meanwhile, a sense of purpose, social connection and curiosity appear almost as important for resilience as exercise and managing blood pressure, blood sugar, cholesterol, alcohol and smoking [1].
Dopamine without the hype. Husain sees the same circuit at both extremes: "almost every drug of addiction hijacks that dopamine system we were talking about. We find when that circuitry is not working, that you can get profound loss of motivation, apathy. When that circuitry is on overdrive, because it's been hijacked by these drugs, you get states of hypermotivation." [1] He adds that it would be "overly simplistic to think, dopamine levels are the only factor that affect our motivation" [1]. He pushes back on the popular idea of "dopamine hits" from scrolling, saying the evidence isn't really very strong [1]. He points to Kent Berridge's work separating wanting, linked to dopamine, from liking, linked to opioid systems. That split explains how people can pursue things they don't enjoy [1]. On Parkinson's, he describes the classic observation that patients can run from a burning house, which suggests slowed movement may partly reflect motivation to act. With Sanjay Manohar, he showed that rewards speed up eye movements in Parkinson's patients and that dopamine speeds them further [1].
Andrew Huberman on depression: anhedonia and the energy trap
Dopamine as craving, and the pleasure-pain balance. Huberman opens his depression episode with a framing from psychiatrist Anna Lembke. Dopamine "is not the molecule of reward, it is the molecule of craving, motivation, and drive." [2] Whenever we pursue something we expect to enjoy, dopamine is released. Soon afterward, below awareness, the brain tips toward pain to rebalance, and we feel that as craving. If we keep chasing, each round releases less dopamine and brings more craving [2]. His lesson: "we should always be cautious of any state of mind or body or any pursuit that leads to very large increases in dopamine" [2].
A case of anhedonia. He describes a 21-year-old man he spoke with, with permission, who became depressed after heavy engagement in highly dopaminergic activities, video games among them [2]. "He is essentially depressed," Huberman says, and whether he meets clinical criteria for addiction "really isn't important." What matters is that he experiences "anhedonia, an inability to experience pleasure from that thing or from anything else" [2]. He now has to do these activities for hours just to feel okay, and nearly everything else has lost its appeal. He is being treated by rebalancing this system [2].
What clinical depression looks like. Major depression affects about 5% of the population and is the fourth leading cause of disability [2]. Huberman separates it from everyday disappointment: a cancelled vacation is not depression. "That's called being bummed out, being sad or disappointed." [2] The clinical signs include grief and sadness, a newly lowered threshold for crying, guilt, and anhedonia: a flat inability to enjoy food, sex, exercise or social life, like biting into your favorite food and tasting nothing [2].
He highlights a less-discussed symptom, "delusional anti-self-confabulation": stories that cast the self as failing even against clear evidence [2]. His example is an injured athlete who says, "I feel like I'm getting weaker and weaker by the day," while the physical therapist sees steady progress. "They're not registering that improvement." [2] There are also "vegetative" symptoms: constant exhaustion, waking at 3, 4 or 5 a.m. and being unable to fall back asleep, disrupted sleep architecture, lost appetite and disrupted appetite hormones, and a shift in cortisol from its healthy morning peak to an evening peak around 9 p.m. [2] Anxiety about the future often layers on top [2].
Mapping symptoms to chemicals. Huberman says there are "at least three major chemical systems in the brain. Norepinephrine, dopamine, and serotonin that relate to and can adjust the symptoms of depression." [2] His rough map: norepinephrine relates to the "psychomotor" symptoms like lethargy and not being able to get out of bed; dopamine relates to anhedonia; serotonin relates to grief, guilt and the more emotional side. In practice, he says, it is rarely that clean [2]. The dopamine link comes partly from the discovery of pleasure pathways (the nucleus accumbens and ventral tegmental area). When these are stimulated, "Animals and humans become very, very motivated to get more stimulation of these pathways," even more than for sex or a drug they are withdrawing from [2].
On medication, SSRIs such as fluoxetine (Prozac) and Zoloft block serotonin reuptake rather than raising the total amount. About a third of people get no benefit, and many of the rest get partial or full relief, often with side effects [2]. Huberman calls SSRIs a "barbed wire" topic because they have saved many lives while also causing problems [2]. Serotonin rises immediately but relief takes about two weeks, which suggests SSRIs work through neuroplasticity [2]. Bupropion (Wellbutrin) raises dopamine and norepinephrine and helps many people without serotonin side effects, but it makes some people anxious or can be habit-forming. That is why good psychiatrists adjust combinations individually [2].
Hormones, stress and genes. About 20% of people with major depression have low thyroid hormone, which "leads to low energy, low metabolism in the brain and body" [2]. Hormonal transitions such as childbirth, certain phases of the menstrual cycle and menopause also raise susceptibility, so Huberman encourages blood work that includes thyroid hormone and cortisol [2]. Repeated long-term stress, such as a draining relationship or breakup, graduate school, illness or loss, sharply raises the risk of depression, often with a delay of months [2]. Carrying certain variants of the serotonin transporter gene 5-HTTLPR "doesn't necessarily mean that you will be depressed, but it greatly shifts your susceptibility to depression under conditions of stress" [2]. Such people can become depressed after just one or two major stressors, rather than the several most people need [2]. If one identical twin has major depression, the other has about a 50% chance; siblings about 25%; half-siblings about 10% [2].
Why behavioral tools are hard to use. This is Huberman's most important point for this insight. Because depression involves low norepinephrine, dopamine and serotonin, behaviors that raise them should help. A cold shower or ice bath reliably releases norepinephrine and epinephrine; a run raises norepinephrine and, if enjoyed, dopamine and probably serotonin; regular exercise is known to protect against depression [2]. The cruel twist is that people deep in depression often cannot summon the energy even to shower, let alone run [2]. He asks listeners to understand that the circuits for motivation are present in everyone but not equally accessible to someone severely depressed. That is why medication and other supports matter, and why any change should be discussed with a physician [2].
Other tools. Huberman ties many forms of depression to chronic inflammation, which diverts tryptophan away from serotonin toward kynurenine and then quinolinic acid, a neurotoxic, pro-depressive compound [2]. EPA omega-3s push back: he says many studies show that at sufficient doses "the relief from depressive symptoms matches the SSRIs," with a threshold of about 1,000 milligrams of EPA per day and 2,000 appearing to work better for many [2]. Exercise pulls kynurenine into muscle. He mentions 150 to 180 minutes per week of zone 2 cardio, plus two to four daily servings of fermented foods [2]. Creatine, generally at 3 to 5 grams per day in studies, has been linked to improved mood and a better SSRI response in women with major depression, with a caution about mania [2]. For treatment-resistant depression, the ketogenic diet has decent evidence, and he encourages raising it with a psychiatrist [2].
Ketamine and psilocybin in the depression episode. Here Huberman already sketches why these drugs are different. A 2019 Science paper from Conor Liston's lab showed that ketamine can rapidly rescue prefrontal circuit function by forming new dendritic spines [2]. His interpretation is that ketamine may help severely depressed people separate from grief and self-attacking narratives that they experience not as something inside them but as who they are. He admits he has always struggled with the phrase "you are not your emotions," and says that may be exactly why a drug that creates distance can help [2]. Psilocybin, by contrast, seems to work through full immersion in the experience. In a May 2021 JAMA Psychiatry trial, between about 50% and 71% of participants showed significant relief, depending on when they were measured [2].
The GIST of every new summary in your inbox, daily or weekly. Free, and you can unsubscribe any time.
Huberman on ketamine: a fast reset for drive that needs behavior to last
Why something new was needed. Monoamine drugs like SSRIs and bupropion work in only about 40% of depressed people who take them, often take weeks or months to kick in, and can bring side effects [3]. Huberman goes further than in the depression episode: he says there is very little, if any, evidence of a monoamine deficiency in any form of depression, even though raising monoamines helps some people [3]. For someone suffering, even another day or hour can feel unmanageable, which is why rapid treatment matters [3].
From a "giving up" test to patients. In the early 1990s, labs using the learned helplessness model, which measures how long a rat or mouse swims before giving up, found that animals given sub-anesthetic ketamine swam much longer [3]. That was a puzzle, because ketamine blocks NMDA receptors, which are critical for neuroplasticity [3]. Around 2000, clinicians tried it. A landmark study of seven people with major depression, given half a milligram per kilogram intravenously, found relief almost immediately that lasted at least three days [3]. Later studies extended its use to suicidality, feelings of helplessness and worthlessness, treatment-resistant depression, bipolar depression, PTSD and more [3].
Fast but short. In Huberman's words, ketamine "can often provide relief from depression almost immediately, meaning same day. However, it is very short-lived." [3] The effect usually wears off after about three days to a week. Stacked regimens, such as twice a week for three weeks, can extend relief for months or more [3]. He believes ketamine acts through at least two and probably three mechanisms: immediate relief tied to the dissociative state, a second process over the following days and weeks, and long-lasting changes in circuit wiring [3]. As he puts it, "The acute or immediate effects of ketamine while one is under the influence of ketamine are just part of the story" [3].
How it restores drive. Ketamine binds NMDA receptors on inhibitory neurons and takes the brake off excitatory neurons in mood circuits, which then fire in bursts. Huberman calls those bursts "the absolute perfect patterns of activity that induce not just short term, but long term changes in the neural circuits associated with reward, with dopamine release, with disappointment, and with mood" [3]. The bursts trigger BDNF release. BDNF knockout mice no longer respond to ketamine in the swim test, and depressed people with a poorly functioning form of BDNF respond much less, which leads Huberman to a model of ketamine acting more or less like a growth factor [3].
At the circuit level, he describes the habenula as a disappointment circuit that normally inhibits the reward pathway, including the ventral tegmental area and nucleus accumbens [3]. Ketamine appears to weaken that inhibition and strengthen links between reward areas and the frontal cortex, which handles figuring out what to do in a situation to get the results you want [3]. The upshot, in his words: "the reward pathway is more available for engagement through daily life activities" [3]. He notes that ketamine is "relieving depression in ways that are entirely different from any other kind of treatment" [3].
The opioid twist. Ketamine is metabolized into hydroxynorketamine, which Huberman describes as highly specific for the mu opioid receptor [3]. In a study by his Stanford colleagues Nolan Williams, Alan Schatzberg and others, patients given naltrexone to block opioid receptors along with ketamine still felt the euphoria and dissociation but no longer got the antidepressant effect [3]. The lesson he draws for ketamine, psilocybin and MDMA alike is that the vivid experience under the drug may not be what produces long-term benefit [3].
Behavior still decides. Huberman is blunt: "ketamine is not a miracle drug" [3]. Circuits are designed to respond to thinking and behavior, not to ketamine; a drug only biases the odds they will be engaged [3]. "But if they continue to engage in pro-depressive behaviors, they are not going to get much if any relief from depression." [3] Those who seek out stimulating work, social engagement, and care for their body and mental health reinforce the changes [3]. He lists antidepressive behaviors such as morning sunlight, regular quality sleep, good nutrition and social engagement, and closes with a colleague's line: "better living through chemistry still requires better living." [3]
Real risks. Ketamine has a high potential for abuse, and people can become addicted even as it degrades their work, relationships and finances [3]. Dose depends heavily on route: only about 25% of an oral dose reaches the bloodstream in active form, and about 35% of a sublingual dose [3]. A "K-hole is a dose that pushes past the dissociative range into a pseudo-anesthetized state. That is dangerous especially with alcohol or barbiturates, and ketamine can trigger seizures in seizure-prone people [3]. His clinician colleagues know of zero published clinical evidence that microdosing ketamine helps depression [3]. And dissociation is actually one of the primary symptoms of PTSD and trauma," which makes the drug's action a genuine conundrum [3].
Where They Agree, and Where They Don't
They agree that low drive can be biological, not a character flaw. Husain moved from seeing motivation as "a personality" to seeing a circuit that can break and be repaired [1]. Huberman repeatedly frames depression as a real, multi-layered biological condition involving several neurochemical systems, hormones, stress and genes [2]. The ketamine episode adds that mood and reward circuits can be physically rewired [3].
They point to the same circuitry. Husain's key region, the ventral striatum or nucleus accumbens [1], is the same reward hub Huberman names in the pleasure pathways that make dopamine a suspect in anhedonia [2] and in the reward pathway ketamine seems to free from the habenula's inhibition [3]. Huberman remarks that "mood disorders that look quite different from one another often depend on the action of the same neurochemicals or neural circuits" [2]. Apathy and anhedonia fit that pattern.
They agree that effort cost is the trap. Husain shows that apathetic people pay a higher cost just to decide [1]. Huberman describes depressed people who cannot summon the energy to shower, let alone run [2]. Both explain why just do it advice fails for someone with a real condition.
They agree that behavior still matters, even with drugs. Husain's agonist restored David [1], but his practical toolkit is behavioral: raise the reward, shrink the effort [1]. Huberman insists ketamine's changes do little unless reinforced by behavior [3].
Where they differ: apathy versus depression. Husain draws a sharp line. David was apathetic but not unhappy, and some depressed people remain motivated [1]. Huberman's depression episode instead folds low drive into depression, mapping lethargy to norepinephrine and anhedonia to dopamine [2]. The difference comes from their vantage points. Husain is a neurologist who sees apathy after strokes, Alzheimer's, Parkinson's and MS [1], while Huberman's episode is about psychiatric major depression [2]. For readers, Husain's distinction is the more useful: losing the will to act and losing the ability to enjoy can travel together, but not always.
Where they differ: how much "dopamine chasing" explains. Huberman's pleasure-pain balance treats repeated big dopamine spikes, including from video games, as a path to anhedonia [2]. Husain agrees that addictive drugs hijack this circuit [1], but he says the evidence for "dopamine hits" from scrolling isn't really very strong [1]. He notes that an older PET study found dopamine release during video game play, but that method couldn't separate wanting from liking [1]. Husain is being cautious about everyday behaviors. Huberman is reasoning from Lembke's clinical addiction model and a patient's experience [2].
Where they differ: what fixes drive chemically. In David, a drug acting directly on dopamine receptors worked where L-dopa and antidepressants did not [1]. Huberman's ketamine episode doubts the monoamine-deficiency idea altogether and credits NMDA-driven plasticity, BDNF and the opioid system instead [3]. These views are not necessarily in conflict. A focal stroke in the ventral striatum is a different problem from diffuse major depression, and Husain himself warns that dopamine is not the only factor [1]. They do show that no single chemical explains lost motivation.
Where they differ: what the drug experience does. In the depression episode, Huberman suggests ketamine's dissociation may help by creating distance from self-attacking stories [2]. In the dedicated ketamine episode, he stresses that the naltrexone study keeps the dissociation but removes the benefit, so the experience may not be what heals [3]. He resolves this by treating the experience as a wavefront that sets off several processes with different time courses [3].
Why It Works
Apathy: a costlier decision, not a missing desire. Husain's model is that the brain values options by reward minus effort, and the basal ganglia pathway turns the winner into action [1]. When that pathway is damaged or underactive, low-reward options stop clearing the bar, while high rewards still do [1]. Imaging in apathetic students adds a second cost: more ventral striatum and medial frontal activity while deciding, meaning thinking about effort is itself effortful [1]. That is why planning ahead helps, since fewer decisions mean less of that cost, and why a bigger or different reward can flip behavior [1]. David's recovery on a D2/D3 agonist, after L-dopa failed, suggests that stimulating the receptors directly can restore the signal when the machinery for making or using dopamine isn't enough [1].
Anhedonia: an exhausted balance and a tangle of systems. Huberman's mechanism for dopamine-driven anhedonia is the pleasure-pain balance: repeated big spikes leave less dopamine per round and more craving, until nothing else appeals [2]. Beyond that, depression involves norepinephrine (energy and getting out of bed), dopamine (pleasure) and serotonin (grief and guilt) [2]. It is amplified by low thyroid, cortisol shifts from repeated stress, gene variants that steepen stress vulnerability, and inflammation that diverts tryptophan toward a neurotoxic compound [2]. Behavioral tools work by raising norepinephrine, dopamine and serotonin, and exercise also pulls kynurenine into muscle [2]. That same energy deficit is why they are hard to start [2].
Ketamine: lifting the brake on reward. Ketamine blocks NMDA receptors on inhibitory neurons, so excitatory neurons fire in bursts that drive plasticity in reward and mood circuits [3]. That burst firing releases BDNF, which is apparently required for the effect [3]. The opioid system is also necessary, since naltrexone abolishes the antidepressant effect [3]. At the circuit level, ketamine weakens the habenula's inhibition of the dopamine-releasing reward pathway and strengthens reward links to the frontal cortex [3]. Because plasticity takes days and involves new genes, proteins and receptors, it best explains the durable relief from repeated treatment rather than the same-day lift [3]. Memantine, another NMDA blocker, has no antidepressant effect, which shows that blocking NMDA alone is not the whole story [3].
Where It Applies, and Where It Doesn't
Ordinary low motivation. If you still enjoy things but struggle to start dull tasks, Husain's framework fits well. The problem is often a low-reward, high-effort option, and the fixes are behavioral: change the incentive, break the task down, plan ahead, get recognition, just start [1]. Huberman's line about the cancelled vacation, "That's called being bummed out, being sad or disappointed," marks the boundary: normal disappointment is not depression [2].
Signs that point beyond a slump. The sources name markers that should prompt care. For apathy, Husain describes a sudden, sweeping change: a sociable, productive person who stops caring, loses job and home, and needs prompts to shower [1]. Apathy is common after stroke and in Alzheimer's, Parkinson's and MS [1], and high apathy scores in healthy older adults come with roughly twice the risk of developing Alzheimer's [1]. For depression, Huberman lists anhedonia across food, sex, exercise and social life; guilt and a lowered crying threshold; anti-self-confabulation; early waking at 3 to 5 a.m.; lost appetite; and constant exhaustion [2]. Low thyroid, hormonal transitions, repeated heavy stress and family history all raise the odds [2]. Any of these calls for a doctor, not a productivity trick.
Apathy without sadness is still a condition. A key lesson from David is that a person can be profoundly unmotivated without feeling unhappy, and antidepressants may not help [1]. Someone who seems fine, just lazy after a medical event may need a neurological assessment.
Where behavioral tools fall short. Husain's levers were developed around reward and effort, and his toolkit is aimed at getting started [1]. Huberman is explicit that people deep in depression often cannot use tools like cold showers or running, and that medication and other supports matter [2]. The evidence on long-horizon perseverance is thin; Husain says long-term planning "has not been studied in great detail" [1].
Where ketamine applies. The research supports ketamine for depression, suicidality and PTSD in clinical settings, especially for people who haven't responded to other treatments [3]. It does not support microdosing [3], unsupervised home use, or combinations with alcohol or barbiturates [3]. Its benefit is short-lived without stacked treatment, and it fades if pro-depressive behaviors continue [3]. It is also a drug of abuse [3]. The evidence also varies in strength. The first clinical study involved seven people [3], and Huberman notes there are other studies with differing regimens [3]. Husain's David is a single case [1]. For psychedelics, Husain only notes emerging research on anhedonia [1].
What To Do With It
If lost motivation comes with the signs above, especially after a medical event or alongside anhedonia, early waking or thoughts of self-harm, talk to a doctor or mental health professional before trying anything on your own. Don't stop or change prescribed medication without them [2].
Sort the problem before fixing it. Ask whether you have stopped wanting to act, stopped enjoying things, or both. Husain shows apathy and depression can occur separately or together [1], and Huberman's anhedonia test is simple: does your favorite food taste like nothing? [2]
Check the body, not just the mind. Ask for blood work that includes thyroid hormone and cortisol, since about 20% of people with major depression have low thyroid hormone and hormonal transitions raise risk [2]. If apathy appeared suddenly or after a stroke, head injury or neurological diagnosis, ask about a neurological assessment; Husain's patient had tiny strokes that showed up only on MRI [1].
Raise the reward on the task. Reframe dull jobs so they carry a reward you care about, as in the man who won't hang pictures but will teach how [1]. Build in recognition along the way, like a manager's "well done" [1].
Shrink the effort and the decisions. Plan your day or week in advance because "Every decision has a cost" [1]. Break projects into if-then steps so a mountain becomes a series of mounds, and just start [1]. Cut distractions: turn off notifications, close email and reduce noise [1].
Practice effort on purpose. Do some unappealing tasks deliberately ("chop wood, carry water"), since "you find your passion by getting good at effort in things that you're not passionate about" [1]. Watch for the slide from one failure into "I'm bad at everything," which Husain warns can shade into depression [1].
Protect your reward system from big spikes. Be cautious of pursuits that bring very large dopamine increases, and don't chase them repeatedly [2]. Huberman suggests a 30-day break can help reset the balance [2].
Use body-based mood tools when you can, and get support when you can't. Regular exercise protects against depression, cold exposure releases norepinephrine, and Huberman cites EPA (about 1,000 to 2,000 milligrams daily), 150 to 180 minutes a week of zone 2 cardio, and fermented foods to fight inflammation [2]. If you cannot summon the energy for any of it, that is a sign to get medical help, not a personal failure [2].
Manage stress, especially with a family history. Repeated heavy stress is the big trigger, and certain genes make it bite after just one or two stressors, so learning to manage stress is one of the best protections [2].
If treatment-resistant, ask about newer options. Raise ketamine (in a supervised clinical setting, often as a stacked regimen), psilocybin trials where legal, or a ketogenic diet with your psychiatrist [2][3]. Avoid microdosing, home use without someone present, and any mixing with alcohol or barbiturates [3].
Pair any drug with "better living." After treatment, deliberately seek stimulating work, social engagement, morning sunlight, good sleep and good nutrition, because a drug only makes the reward pathway "more available for engagement through daily life activities" [3]. Keep purpose, curiosity and social connection in your life; Husain links them to brain resilience as we age [1].